Salud financiera de hoja de balance de Willow Biosciences

Salud financiera controles de criterios 4/6

Willow Biosciences tiene un patrimonio de los accionistas total de CA$3.4M y una deuda total de CA$676.0K, lo que sitúa su ratio deuda-patrimonio en 19.7%. Sus activos y pasivos totales son CA$6.7M y CA$3.2M respectivamente.

Información clave

44.4%

Ratio deuda-patrimonio

CA$685.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CA$2.00m
Patrimonio	CA$1.54m
Total pasivo	CA$3.03m
Activos totales	CA$4.57m

Actualizaciones recientes sobre salud financiera

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

May 20

Recent updates

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

Apr 11

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

Dec 20

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

Sep 02

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

May 20

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Jan 19

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$4.2M) de WLLW superan a sus pasivos a corto plazo (CA$1.8M).

Pasivo a largo plazo: Los activos a corto plazo de WLLW (CA$4.2M) superan a sus pasivos a largo plazo (CA$1.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: WLLW tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de WLLW ha pasado de 56.7% a 44.4% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: WLLW tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: WLLW tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 12.2% cada año

Salud financiera de hoja de balance de Willow Biosciences

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

Willow Biosciences to Commence Trading on The OTCQX® Best Market

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022)

New major risk - Market cap size

New minor risk - Shareholder dilution

Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.032 loss in 3Q 2022)

Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc

Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc

Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding

Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding

Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding

Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding

Willow Biosciences Inc. Announces Successful Completion of R&D Program on Covid

Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced Cost

Willow Biosciences Inc. Announces Board Changes

New major risk - Market cap size

Willow Biosciences Inc. Announces Executive Changes

Full year 2022 earnings released: CA$0.12 loss per share (vs CA$0.051 loss in FY 2021)

Willow Biosciences Inc. Provides Earnings Guidance for the Year 2023

Insufficient new directors

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.031 profit in 3Q 2021)

Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as its CEO

Willow Biosciences Inc. Completes Proof of Concept Work and Starts Yeast Strain Optimization and Process Development Toward Commercial Production of Astaxanthin

Independent Director recently bought CA$63k worth of stock

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.053 profit in 2Q 2021)

Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as Interim President

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.10 loss in 1Q 2021)

Insufficient new directors

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020)

Willow Biosciences Inc. Announces Results of its in Vitro Analysis and First to Report Topical Clinical Study on Cannabigerol in Collaboration with Signum Biosciences

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

President recently bought CA$60k worth of stock

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

First quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.018 loss in 1Q 2020)

Willow Biosciences Inc., Annual General Meeting, Apr 28, 2021

Independent Director exercised options to buy CA$187k worth of stock.

New 90-day high: CA$1.81

Willow Biosciences Inc. Advances its Work on Tetrahydrocannabinol and Plans to Launch in the Canadian Market

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Willow Biosciences Provides Update on Cannabigerol Research Studies

New 90-day high: CA$1.19

New 90-day high: CA$0.81

Willow Biosciences Advances Its Commericalization Plan

Willow Biosciences Inc. announced that it has received $1.168596 million in funding

President recently bought CA$192k worth of stock

Willow Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

New 90-day low: CA$0.55

Willow Biosciences Partners with Researchers At the University of Lethbridge and University of Calgary to Study Effects of Non-Psychoactive Cannabinoids on Pain, Inflammation and Depression

Willow Biosciences Inc. Announces Successful Production of Pure Cannabigerol

New 90-day high - CA$0.81

Earnings released

New 90-day high - CA$0.57

Willow Biosciences to Commence Trading on The OTCQX® Best Market

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera